Identifying candidate hirschsprung disease-associated RET variants

American Journal of Human Genetics

Volumn 76, Issue 5, 2005, Pages 850-858

  Burzynski, Grzegorz M ^a   Nolte, Ilja M ^a   Bronda, Agnes ^a   Bos, Krista ^a   Osinga, Jan ^a   Menacho, Ivan Plaza ^a   Twigt, Bas ^a   Maas, Saskia ^c   Brooks, Alice S ^d   Verheij, Joke B G M ^b   Buys, Charles H C M ^a,b   Hofstra, Robert M W ^a,e  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e Department of Medical Genetics ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GENOMIC DNA; PROTEIN RET; TRANSCRIPTION FACTOR;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA SEQUENCE; EXON; GENE DISRUPTION; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CONSERVATION; GENETIC MARKER; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HIRSCHSPRUNG DISEASE; HOMOZYGOSITY; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; INTRON; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY;

VERTEBRATA;

EID: 20244382845     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/429589     Document Type: Article

References (19)

1. Amiel J, Lyonnet S (2001) Hirschsprung disease, associated syndromes, and genetics: a review. J Med Genet 38:729-739
2. Badner J, Sieber W, Garver K, Chakravarti A (1990) A genetic study of Hirschsprung disease. Am J Hum Genet 46:568-580
3. Bolk S, Pelet A, Hofstra RMW, Angrist M, Salomon R, Croaker D, Buys CHCM, Lyonnet S, Chakravarti A (2000) A human model for multigenic inheritance: phenotypic expression in Hirschsprung disease requires both the RET gene and a new 9q31 locus. Proc Nad Acad Sci USA 97:268-273
4. Borrego S, Wright F, Fernandez R, Williams N, Lopez-Alonso M, Davuluri R, Antinolo G, Eng C (2003) A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma. Am J Hum Genet 72:88-100
5. Burzynski GM, Nolte IM, Osinga J, Ceccherini I, Twigt B, Maas S, Brooks A, Verheij J, Plaza Menacho I, Buys CHCM, Hofstra RMW (2004) Localizing a putative mutation as the major contributor to the development of sporadic Hirschsprung disease to the RET genomic sequence between the promoter region and exon 2. Eur J Hum Genet 12:604-612
6. Ceccherini I, Hofstra RM, Luo Y, Stulp RP, Barone V, Stelwagen T, Bocciardi R, Nijveen H, Bolino A, Seri M (1994) DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret proto-oncogene. Oncogene 9:3025-3029
7. Davidson B, Goldberg I, Tell L, Vigdorchik S, Baekelandt M, Berner A, Kristensen GB, Reich R, Kopolovic J (2004) The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions. Clin Exp Metastasis 21:191-199
8. Falk CT, Rubinstein P (1987) Haplotype relative risks: an easy reliable way to construct a proper control sample for risk calculations. Ann Hum Genet 51:227-233
9. Fitze G, Appelt H, Konig I, Gorgens H, Stein U, Walther W, Gossen M, Schreiber M, Ziegler A, Roesner D, Schackert HK (2003) Functional haplotypes of the RET proto-oncogene promoter are associated with Hirschsprung disease (HSCR). Hum Mol Genet 12:3207-3214
10. Gabriel SB, Salomon R, Pelet A, Angrist M, Amiel J, Fornage M, Attie-Bitach T, Olson JM, Hofstra R, Buys C, Steffann J, Munnich A, Lyonnet S, Chakravarti A (2002) Segregation at three loci explains familial and population risk in Hirschsprung disease. Nat Genet 31:89-93
11. Garcia-Barcelo M, Ganster RW, Lui VC, Leon TY, So MT, Lau AM, Fu M, Sham MH, Knight J, Zannini MS, Sham PC, Tam PK (2005) TTF-1 and RET promoter SNPs: regulation of RET transcription in Hirschsprung's disease. Hum Mol Genet 14:191-204
12. Griseri P, Bachetti T, Puppo F, Lantieri F, Ravazzolo R, Devoto M, Ceccherini I (2005) A common haplotype at the 5′ end of the RET proto-oncogene underlies genetic susceptibility to HSCR development through reduced gene expression. Hum Mutat 25:189-195
13. Hofstra RM, Wu Y, Stulp RP, Elfferich P, Osinga J, Maas SM, Siderius L, Brooks AS, vd Ende JJ, Heydendael VM, Severijnen RS, Bax KM, Meijers C, Buys CH (2000) RET and GDNF gene scanning in Hirschsprung patients using two dual denaturing gel systems. Hum Mutat 15:418-429
14. Holschneider A (1982) Hirschsprung's congenital megacolon: the concept of physiopathology and therapy. Med Welt 33:210-213
15. Manie S, Santoro M, Fusco A, Billaud M (2001) The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet 17:580-589
16. Oikawa T (2004) ETS transcription factors: possible targets for cancer therapy. Cancer Sci 95:626-633
17. Sancandi M, Griseri P, Pesce B, Patrone G, Puppo F, Lerone M, Martucciello G, Romeo G, Ravazzolo R, Devoto M, Ceccherini I (2003) Single nucleotide polymorphic alleles in the 5′ region of the RET proto-oncogene define a risk haplotype in Hirschsprung disease. J Med Genet 40:714-718
18. Spielman RS, Ewens WJ (1996) The TDT and other family-based tests for linkage disequilibrium and association. Am J Hum Genet 59:983-989
19. Terwilliger JD, Ott J (1992) A haplotype-based "haplotype relative risk" approach to detect allelic associations. Hum Hered 42:337-346